Chemours (CC)
(Delayed Data from NYSE)
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.79 USD
-0.66 (-3.23%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum F VGM
Zacks News
Chemours (CC) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Lower volumes and prices hurt Chemours' (CC) top line in the first quarter.
Chemours (CC) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Chemours (CC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Chemours (CC) Q1 Earnings Surpass Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 28% and 0.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Chemours (CC) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stepan Co. (SCL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Stepan Co. (SCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemours (CC) Recently Broke Out Above the 20-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Chemours (CC) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?
Company News for Apr 1, 2024
by Zacks Equity Research
Companies In The News Are: RH, AMC, CC, WBA.
Chemours (CC) Q4 Earnings Beat, Revenue Miss Estimates
by Zacks Equity Research
Chemours (CC) fourth-quarter earnings beat estimates, while sales miss despite growth across TT and TSS segments.
Chemours (CC) Q4 Earnings Top Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of 6.90% and 0.69%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Chemours (CC) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Should Value Investors Buy Chemours (CC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Eastman Chemical (EMN) Gains on Cost Cuts and Innovation
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.
LyondellBasell's (LYB) Petrothene T3XL7420 to Optimize Production
by Zacks Equity Research
Petrothene T3XL7420 by LyondellBasell (LYB) passes extensive testing and certification procedures to ensure its quality and dependability.
Chemours (CC), DuPont & Corteva Back U.S. Water System Deal
by Zacks Equity Research
Chemours (CC), DuPont & Corteva do not intend to exercise the opt-out option and extend support to PFAS Deal with the U.S. Water System.
Air Products and Chemicals (APD) Up 0.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Air Products and Chemicals (APD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Chemours (CC) Sets Up International F-gas Lifecycle Program
by Zacks Equity Research
This program by Chemours (CC) will incorporate worldwide monitoring to stimulate further adoption, partnerships and reclamation.
Chemours (CC) Boosts Low GWP HFC-152a Production by 20%
by Zacks Equity Research
Chemours (CC) is increasing HFC-152a production by 20% at its Texas facility to meet the growing demand for eco-friendly propellants and foam-blowing agents.
Chemours (CC) Q3 Earning Miss, Titanium Technologies Hurt Sales
by Zacks Equity Research
Chemours (CC) lags estimates in Q3 amid lower volumes and soft demand.
These 2 Basic Materials Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Compared to Estimates, Chemours (CC) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Chemours (CC) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Chemours (CC) delivered earnings and revenue surprises of -16.88% and 3.63%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights LyondellBasell, Chemours, Axalta Coating Systems and Ashland
by Zacks Equity Research
LyondellBasell, Chemours, Axalta Coating Systems and Ashland are included in this Analyst Blog.
4 Chemical Stocks Set to Pull Off a Beat This Earnings Season
by Anindya Barman
While softer demand in certain end markets is likely to be a drag, LyondellBasell (LYB), Chemours (CC), Axalta Coating Systems (AXTA) and Ashland (ASH) are likely to have benefited from cost and pricing actions.